SHAP analyses revealed that relapse timing reflects distinct biological patterns: Early Relapse is primarily driven by tumor burden and systemic inflammation (advanced stage, positive cytology, high CA125, thrombocytosis), whereas Late Relapse is associated with invasion-related features (LVSI, tumor size, ARID1A loss). This evidence concerns the gene ARID1A and thrombocytosis disease.